August 12, 2026

To	To
The Manager, Listing Department	The General Manager, Listing Department
National Stock Exchange of India Ltd.	**BSE Limited**
Plot no. C/1 G Block,	Phiroze Jeejeebhoy Towers,
Bandra-Kurla Complex, Bandra (East),	Dalal Street,
Mumbai- 400 051	Mumbai- 400 001
Symbol: **BLISSGVS**	Scrip Code: **506197**

Subject: Outcome of Board Meeting held on Wednesday, August 12, 2026

Dear Sir/Madam,

We wish to inform you that the Board Meeting of the Company was held today i.e. on **Wednesday, August 12, 2026**, through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM"), with the deemed venue being the Registered Office of the Company. Pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matter amongst others:

1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. A copy of the unaudited standalone and consolidated financial results, along with the Limited Review Report of the Auditors, are enclosed below.

2. The draft of the Postal Ballot Notice seeking the approval of members of the Company for the appointment of Mr. Santosh Parab (DIN: 01622988) as a Director of the Company in the capacity of Non-Executive Non-Independent Director of the Company.

The Board of Directors meeting commenced at 4:22 p.m. and concluded at 6:15 p.m.

Kindly take the above information on record and acknowledge it.

Thanking you.
Yours faithfully,

For **Bliss GVS Pharma Limited**

ADITI HIMANSHU BHATT
Digitally signed by ADITI HIMANSHU BHATT
Date: 2026.08.12 19:26:44 +05'30'

Aditi Bhatt
Company Secretary

Encl: As above

BLISS GVS PHARMA LIMITED

Regd. Office - 102, Hyde Park, Sakivihar Road, Andheri East- Mumbai-400072

CIN - L24230MH1984PLC034771

Statement of Un-Audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2026

₹ in Lakh

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter Ended			Year Ended	Quarter Ended			Year Ended
		June 30, 2026	Mar 31, 2026	June 30, 2025	Mar 31, 2026	June 30, 2026	Mar 31, 2026	June 30, 2025	Mar 31, 2026
		Un-Audited	Audited (Refer Note 7)	Un-Audited	Audited	Un-Audited	Audited (Refer Note 7)	Un-Audited	Audited
I	Revenue from Operations	22,158.51	21,153.73	16,336.43	72,980.76	28,557.56	25,699.32	20,746.92	92,711.28
II	Other Income	876.16	930.18	1,059.27	4,371.87	959.97	1,116.13	3,545.40	7,352.98
III	**Total Income (I+II)**	**23,034.67**	**22,083.91**	**17,395.70**	**77,352.63**	**29,517.53**	**26,815.45**	**24,292.32**	**1,00,064.26**
IV	Expenses								
a.	Cost of Materials Consumed	9,073.63	10,227.71	8,884.83	36,046.49	9,463.65	11,125.51	9,341.23	38,625.52
b.	Purchases of Stock-in-Trade	-	778.69	-	778.69	1,509.81	1,821.12	2,057.47	6,125.24
c.	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	0.17	(1,264.71)	(1,720.56)	(2,561.66)	470.99	(1,600.83)	(2,209.55)	(2,244.31)
d.	Employee Benefits Expense	3,656.66	3,183.18	2,810.04	12,149.78	4,304.72	3,613.81	3,100.26	13,642.75
e.	Finance Costs	38.92	181.14	511.23	1,111.36	57.94	200.75	547.15	1,200.68
f.	Depreciation and Amortisation Expenses	903.03	784.15	768.46	3,101.95	993.75	867.07	820.13	3,348.34
g.	Other Expenses	4,241.34	3,814.09	3,085.39	13,164.01	5,168.36	6,295.69	4,324.54	20,158.41
	Total Expenses	**17,913.75**	**17,704.25**	**14,339.39**	**63,790.62**	**21,969.22**	**22,323.12**	**17,981.23**	**80,856.63**
V	**Profit before exceptional Items and tax (III-IV)**	**5,120.92**	**4,379.66**	**3,056.31**	**13,562.01**	**7,548.31**	**4,492.33**	**6,311.09**	**19,207.63**
VI	Less: Exceptional Items (Refer Note 5)	-	35.82	-	(215.55)	-	2.66	-	(248.71)
VII	**Profit before Tax (V-VI)**	**5,120.92**	**4,415.48**	**3,056.31**	**13,346.46**	**7,548.31**	**4,494.99**	**6,311.09**	**18,958.92**
VIII	Tax Expenses								
	Current Tax	958.09	1,099.64	1,149.69	4,142.49	1,687.74	1,976.40	1,944.28	6,807.23
	Deferred Tax	330.02	67.58	(303.88)	(594.69)	747.82	(1,188.11)	(174.53)	(1,433.12)
	Taxation adjustment of earlier years Excess(-)/Short(+)	(28.96)	6.01	105.21	111.22	(24.45)	6.83	105.21	112.04
IX	**Net Profit for the period/ year (VII-VIII)**	**3,861.77**	**3,242.25**	**2,105.29**	**9,687.44**	**5,137.20**	**3,699.87**	**4,436.13**	**13,472.77**
X	**Other Comprehensive Income**								
	i. Items that will not be re-classified to Profit or Loss								
	(i) Remeasurement of (loss)/ gain of Defined Benefit Plan	(86.34)	8.07	(12.73)	(24.00)	(86.34)	25.80	(12.73)	(6.27)
	(ii) Tax relating to items that will not be reclassified to Profit or Loss	21.73	(2.99)	3.20	6.04	21.73	(7.45)	3.20	1.58
	ii. Items that will be re-classified to Profit or Loss								
	(i) Exchange differences in translating the financial statements of foreign operations	-	-	-	-	(153.33)	(415.30)	794.77	207.89
	(ii) Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	156.84	(200.03)	-
XI	**Total Comprehensive Income for the period/ year**	**3,797.16**	**3,247.33**	**2,095.76**	**9,669.48**	**4,919.26**	**3,459.76**	**5,021.34**	**13,675.97**
XII	**Profit attributable to :**								
	i. Owners of the Company	-	-	-	-	5,009.74	3,557.51	4,303.79	12,912.92
	ii. Non-Controlling Interests	-	-	-	-	127.46	142.36	132.34	559.85
XIII	**Other Comprehensive Income/ (Loss) attributable to :**								
	i. Owners of the Company	-	-	-	-	(217.94)	(244.09)	585.21	199.22
	ii. Non-Controlling Interests	-	-	-	-	-	3.98	-	3.98
XIV	**Total Comprehensive Income attributable to :**								
	i. Owners of the Company	-	-	-	-	4,791.80	3,313.42	4,889.00	13,112.14
	ii. Non-Controlling Interests	-	-	-	-	127.46	146.34	132.34	563.83
XV	Paid up equity share capital (Face Value ₹ 1/-)	1,060.56	1,057.89	1,054.98	1,057.89	1,060.56	1,057.89	1,054.98	1,057.89
XVI	Other Equity	-	-	-	1,14,460.93	-	-	-	1,18,232.07
XVII	Earnings Per Share Basic and Diluted (*Not Annualised) (₹)								
	i. Basic	3.65*	3.06*	2.00*	9.17	4.73*	3.37*	4.08*	12.23
	ii. Diluted	3.58*	2.99*	1.98*	9.00	4.65*	3.28*	4.04*	12.00

Notes:

1 The above un-audited standalone and consolidated financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 12, 2026. These standalone and consolidated un-audited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

2 The above un-audited standalone and consolidated financial results for the quarter ended June 30, 2026 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors have issued limited review reports with unmodified conclusion on the un-audited standalone and consolidated financial results.

3 As the Group's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.

4 Employee Benefit Expenses includes Share Based Payment expense on account of ESOP Scheme, 2019 of ₹ 297.04 Lakh (quarter ended June 30, 2025 ₹ 140.07 Lakh) as per Ind AS 102 "Share based Payment" for the quarter ended June 30, 2026.

5 Pursuant to the implementation of the New Labour Codes with effect from November 21, 2025, the Company and the Group had reassessed its employee benefit obligations and recognised an incremental expense of ₹ 215.55 Lakh and ₹ 248.71 Lakh in standalone and consolidated financials respectively for the year ended March 31, 2026, under Exceptional Items as past service cost.

6 During the quarter ended June 30, 2026, the Company has allotted 2,67,250 equity shares of ₹ 1 each fully paid, on exercise of stock options by employees in accordance with the Company's ESOP Scheme, 2019. The outstanding number of options as at June 30, 2026 are 22,36,250.

7 The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year and the published year to date un-audited figures upto the third quarter of the previous financial year, which were subject to limited review.

For BLISS GVS PHARMA LIMITED

Narsimha Shibroor Kamath
Managing Director
DIN : 00140593

Place : Mumbai
Date : August 12, 2026

BLISS GVS PHARMA LTD. MUMBAI

KALYANIWALLA
& MISTRY LLP

CHARTERED ACCOUNTANTS

REVIEW REPORT

TO THE BOARD OF DIRECTORS
BLISS GVS PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Bliss GVS Pharma Limited** ("the Company") for the quarter ended June 30, 2026, together with notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement which is the responsibility of the Company's Management and reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 12, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Attention is drawn to the fact that the figures for the quarter ended March 31, 2026, as reported in the Statement are the balancing figures between audited figures in respect of the full financial year ended March 31, 2026, and published unaudited year to date figures up to the end of the third quarter of the previous financial year, which were reviewed by us.

*For **KALYANIWALLA & MISTRY LLP***
CHARTERED ACCOUNTANTS
Firm Regn. No.: 104607W / W100166

JAMSHED KEKAS UDWADIA
Digitally signed by JAMSHED KEKAS UDWADIA
Date: 2026.08.12 19:21:21 +05'30'

KALYANIWALLA & MISTRY LLP MUMBAI

Jamshed K. Udwadia
PARTNER
M. No.: 124658
UDIN: 26124658JXGHCO8689
Mumbai, August 12, 2026

REVIEW REPORT

TO THE BOARD OF DIRECTORS
BLISS GVS PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Bliss GVS Pharma Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and reviewed by the Parent's Audit Committee and approved by the Parent's Board of Directors at their respective meetings held on August 12, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

   A. **Incorporated in India:**
   1. Kremoint Pharma Private Limited
      1.1 Eipii Exports Private Limited (Subsidiary of 1. above)

   B. **Incorporated outside India:**
   2. Bliss GVS International Pte. Ltd., Singapore
      2.1 Asterisk Lifesciences (GH) Limited, Ghana (Subsidiary of 2. above)
      2.2 Theralife Pharma Ltd, Kenya (Subsidiary of 2. above)
      2.3 Theralife Pharma RDC Private Limited, Democratic Republic of the Congo (Subsidiary of 2. above)
   3. Asterisk Lifesciences Limited, United Kingdom

KALYANIWALLA & MISTRY LLP MUMBAI

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6(a) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. (a) We did not review the interim financial information of three subsidiaries and three step-down subsidiaries included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 9,607.05 lakh, total net profit after tax (before consolidation adjustments) of Rs. 3,323.05 lakh, total comprehensive income (before consolidation adjustments) of Rs. 3,055.09 lakh for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

(b) The Statement includes the interim financial information of one step-down subsidiary which has not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. Nil, total net profit after tax (before consolidation adjustments) of Rs. Nil and total comprehensive income (before consolidation adjustments) of Rs. Nil for the quarter ended June 30, 2026, as considered in the Statement. According to the information and explanations given to us by the Parent's Management, the interim financial information of this subsidiary is not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.

7. Attention is drawn to the fact that the figures for the quarter ended March 31, 2026, as reported in the Statement are the balancing figures between audited figures in respect of the full financial year ended March 31, 2026, and published unaudited year to date figures up to the end of the third quarter of the previous financial year, which were reviewed by us.

For ***KALYANIWALLA & MISTRY LLP***
CHARTERED ACCOUNTANTS
Firm Registration No. 104607W/W100166

JAMSHED KEKAS UDWADIA

Digitally signed by JAMSHED KEKAS UDWADIA
Date: 2026.08.12 19:22:02 +05'30'

KALYANIWALLA & MISTRY LLP MUMBAI

Jamshed K. Udwadia
PARTNER
M. No.: 124658
UDIN: 26124658TBDPCL8988
Mumbai, August 12, 2026